NDAQ Nasdaq Inc

Zealand Pharma (Nasdaq:ZEAL), a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market this week.

Britt Meelby Jensen, President and CEO of Zealand Pharma A/S, celebrates Zealand Pharma's IPO at the Nasdaq MarketSite. The Zealand Pharma team celebrates their IPO at the Nasdaq MarketSite in Times Square.

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/5499f1d5-5aea-4c2a-a4d4-37be20473f46

http://www.globenewswire.com/NewsRoom/AttachmentNg/79d11059-5065-4457-b85c-69c3425152dd

Zealand Pharma has a portfolio that includes two approved products for the treatment of type 2 diabetes: Soliqua® 100/33 and Adlyxin®/Lyxumia®. Both products were launched in the U.S. earlier this year by its partner Sanofi. In addition, their pipeline includes gastrointestinal and metabolic product candidates, addressing specialty diseases with significant unmet medical needs.

“We are very excited and believe it is the perfect time for Zealand Pharma to list in the United States. In June 2017, we achieved positive clinical results for two late stage product candidates, thus the listing and the capital raised in conjunction with the listing should enable us to progress development of these products,” said Britt Meelby Jensen, President and CEO of Zealand Pharma A/S.

“Zealand Pharma has a track record of successfully inventing and developing their novel peptide-based product candidates. Their history of innovation makes them a perfect fit into the Nasdaq family of disruptors, and we are proud to stand by them on their journey as a public company,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq.  Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About NasdaqNasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

- NDAQG -

Media Relations Contacts:
Stephanie Lowenthal 
(646) 441-5073
Stephanie.Lowenthal@nasdaq.com

Emily Pan
(646) 441-5120
emily.pan@nasdaq.com